<?xml version='1.0' encoding='utf-8'?>
<document id="24285344"><sentence text="Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator."><entity charOffset="74-82" id="DDI-PubMed.24285344.s1.e0" text="TM-25659" /></sentence><sentence text="The in vitro metabolic stability and transport mechanism of TM-25659, a novel TAZ modulator, was investigated in human hepatocytes and human liver microsomes (HLMs) based on the preferred hepatobiliary elimination in rats"><entity charOffset="60-68" id="DDI-PubMed.24285344.s2.e0" text="TM-25659" /></sentence><sentence text=" In addition, the in vitro transport mechanism and transporter-mediated drug-drug interactions were evaluated using oocytes and MDCKII cells overexpressing clinically important drug transporters" /><sentence text=" After a 1 h incubation in HLMs, 92" /><sentence text="9 ± 9" /><sentence text="5% and 95" /><sentence text="5 ± 11" /><sentence text="6% of the initial TM-25659 remained in the presence of NADPH and UDPGA, respectively"><entity charOffset="18-26" id="DDI-PubMed.24285344.s8.e0" text="TM-25659" /><entity charOffset="55-60" id="DDI-PubMed.24285344.s8.e1" text="NADPH" /><entity charOffset="65-70" id="DDI-PubMed.24285344.s8.e2" text="UDPGA" /><pair ddi="false" e1="DDI-PubMed.24285344.s8.e0" e2="DDI-PubMed.24285344.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24285344.s8.e0" e2="DDI-PubMed.24285344.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24285344.s8.e0" e2="DDI-PubMed.24285344.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24285344.s8.e1" e2="DDI-PubMed.24285344.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24285344.s8.e1" e2="DDI-PubMed.24285344.s8.e2" /></sentence><sentence text=" Uptake of TM-25659 readily accumulated in human hepatocytes at 37 ºC (i"><entity charOffset="11-19" id="DDI-PubMed.24285344.s9.e0" text="TM-25659" /></sentence><sentence text="e" /><sentence text=" 6" /><sentence text="7-fold greater than that at 4 ºC), in which drug transporters such as OATP1B1 and OATP1B3 were involved" /><sentence text=" TM-25659 had a significantly greater basal to apical transport rate (5"><entity charOffset="1-9" id="DDI-PubMed.24285344.s13.e0" text="TM-25659" /></sentence><sentence text="9-fold) than apical to basal transport rate in the Caco-2 cell monolayer, suggesting the involvement of an efflux transport system" /><sentence text=" Further studies using inhibitors of efflux transporters and overexpressing cells revealed that MRP2 was involved in the transport of TM-25659"><entity charOffset="134-142" id="DDI-PubMed.24285344.s15.e0" text="TM-25659" /></sentence><sentence text=" These results, taken together, suggested that TM-25659 can be actively influxed into hepatocytes and undergo biliary excretion without substantial metabolism"><entity charOffset="47-55" id="DDI-PubMed.24285344.s16.e0" text="TM-25659" /></sentence><sentence text=" Additionally, TM-25659 inhibited the transport activities of OATP1B1 and OATP1B3 with IC50 values of 36"><entity charOffset="15-23" id="DDI-PubMed.24285344.s17.e0" text="TM-25659" /></sentence><sentence text="3 and 25" /><sentence text="9 μm, respectively" /><sentence text=" TM-25659 (100 μm) increased the accumulation of the probe substrate by 160% and 213%, respectively, through the inhibition of efflux function of P-gp and MRP2" /><sentence text=" In conclusion, OATP1B1, OATP1B3, P-gp and MRP2 might be major transporters responsible for the pharmacokinetics and drug-drug interaction of TM-25659, although their contribution to in vivo pharmacokinetics needs to be further investigated"><entity charOffset="142-150" id="DDI-PubMed.24285344.s21.e0" text="TM-25659" /></sentence><sentence text="" /></document>